3 Anti-Retroviral Ingredients, Paracetamol Dosages and Specialty Formulations Stocks With a Strong Future Roadmap: Laurus Labs, Granules India and Rubicon Research

API and formulation maker stocks give investors exposure to the companies that make the ingredients and finished tablets behind generic medicines. Laurus Labs, Granules India and Rubicon Research cover a diversified ingredient and formulation group, a leading paracetamol and finished dosage maker and a specialty formulations developer.

This list covers three API and formulation maker stocks with complete current figures: Laurus Labs, Granules India and Rubicon Research. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are API and Formulation Maker Stocks?

API and formulation maker stocks are listed pharma companies that produce active pharmaceutical ingredients, intermediates and finished dosage forms for customers in India and abroad. Results depend on approvals, plant utilisation and the share of higher-value products.

API and Formulation Maker Stocks at a Glance

On valuation, Granules India trades at a P/E below the industry P/E, while Laurus Labs and Rubicon Research trade above it, which reflects the growth the market already expects. Readers comparing API and formulation maker stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in API and formulation maker stocks can use the coming numbers to test whether growth is holding.

Why Do API and Formulation Maker Stocks Have a Strong Roadmap in India?

API and formulation maker stocks have a strong roadmap in India because global drug makers want reliable Indian suppliers, and companies are moving from basic ingredients to higher-value finished products.

• Value chain shift. Moving into finished dosages earns better margins than selling only ingredients.
• Specialty products. Complex generics need technical skill and earn better pricing.
• Capacity additions. New plants for formulations and biotech widen the product basket.

Why Laurus Labs Features Among These API and Formulation Maker Stocks

Among the API and formulation maker stocks on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.

The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.

Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore.

Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.

Why Granules India Features Among These API and Formulation Maker Stocks

Among the active ingredient shares on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Why Rubicon Research Features Among These API and Formulation Maker Stocks

Among the three companies on this list, Rubicon Research is a pharmaceutical formulations company that develops and sells specialty and complex generic products, with the United States as its main market.

In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%.

Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0.

Roadmap: The company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.

What to watch: Follow new product approvals and launches in the United States.

Laurus Labs vs Granules India vs Rubicon Research on Key Financials

The table below sets the three API and formulation maker stocks side by side on revenue, profit and margin, using reported figures.

Rubicon Research posts the highest return on equity in this group at 19.1%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Rubicon Research shows the fastest revenue growth with a 52.0% compound annual rate. A useful habit with API and formulation maker stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in API and Formulation Maker Stocks

Every theme carries risks that deserve a check before any decision. For these API and formulation maker stocks, the main points are: Long-term active ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory audits. Plant inspections can affect supply and approvals.
• Price erosion. Generic prices in regulated markets can change with competition.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter API and formulation maker stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on API and Formulation Maker Stocks

API and formulation maker stocks reward investors who study approvals, capacity and product mix. Laurus Labs, Granules India and Rubicon Research each show a different route to higher-value pharma. Based on the 20 October 2026 close, Laurus Labs trades at Rs 2,069, Granules India at Rs 806.05 and Rubicon Research at Rs 1,486.7. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these API and formulation maker stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track API and formulation maker stocks, set price alerts and get research-backed stock ideas.

What are API and formulation maker stocks?

Ans. API and formulation maker stocks are listed pharma companies that produce active pharmaceutical ingredients, intermediates and finished dosage forms for customers in India and abroad. Results depend on approvals, plant utilisation and the share of higher-value products. This list looks at three of them, Laurus Labs, Granules India and Rubicon Research, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which API and formulation maker stocks are covered in this list?

Ans. This list covers Laurus Labs, Granules India and Rubicon Research. Based on the 20 October 2026 close, Laurus Labs traded at Rs 2,069, Granules India at Rs 806.05 and Rubicon Research at Rs 1,486.7. Their return on equity ranges from 11.7% to 19.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 52.0%.

Why do API and formulation maker stocks have a strong future roadmap in India?

Ans. API and formulation maker stocks have a strong roadmap in India because global drug makers want reliable Indian suppliers, and companies are moving from basic ingredients to higher-value finished products. The main drivers are as follows. Value chain shift. Moving into finished dosages earns better margins than selling only ingredients. Specialty products. Complex generics need technical skill and earn better pricing. Capacity additions. New plants for formulations and biotech widen the product basket. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Laurus Labs performed financially?

Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

How has Rubicon Research performed financially?

Ans. Revenue rose from Rs 330 crore in FY22 to Rs 1,762 crore in FY26, a compound annual growth rate of 52.0%. Net profit grew from Rs 91.0 crore in FY24 to Rs 247 crore in FY26, which works out to a compound annual growth rate of 64.7%. In the June 2026 quarter, revenue grew 52.9% year on year to Rs 540 crore, while net profit rose 95.8% to Rs 84.8 crore. The company has a return on equity of 19.1%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 24,654 crore. The stock trades at a P/E of 85.5, above the industry P/E of 36.0. Looking ahead, the company builds differentiated products that need technical skill and earn better pricing than basic generics. A growing list of approved products and an own-label model give it room to widen its portfolio.

What risks should investors check before buying API and formulation maker stocks?

Ans. Investors should check a few risks before buying API and formulation maker stocks. Regulatory audits. Plant inspections can affect supply and approvals. Price erosion. Generic prices in regulated markets can change with competition. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of API and formulation maker stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.